AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8626983
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation
Trial: 30984320
Drug: Occlusal appliance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusal appliance (OA) with nonsteroidal anti‐inflammatory drug (NSAID) therapy (nimesulide)
Trial: 29136001
Drug: Combination Intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Intervention Strategy (CIS)
Trial: 18077134
Drug: 15 mg/d
RxNorm normalized name: Valtoco, 15 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/d of supplemental Zn
Trial: 18424598
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g of pureed strawberries (15 micromol anthocyanin)
Trial: 18424598
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g of pureed strawberries (30 micromol anthocyanin)
Trial: 22839504
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline injection)
Trial: 11830801
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated varicella vaccine
Trial: 3902184
Drug: Amantadine hydrochloride
RxNorm normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine hydrochloride 100 mg twice a day
Trial: 3045113
Drug: Sertraline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (100 mg)
Trial: 15209786
Drug: Flashlamp-pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flashlamp-pulsed dye laser treatment
Trial: 3132866
Drug: Flumazenil (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.8 mg/70 kg)
Trial: 30668352
Drug: Mastiha (2.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mastiha (2.8 g/day)
Trial: 28586537
Drug: Vericiguat 10
RxNorm normalized name: vericiguat 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vericiguat 10 mg once daily
Trial: 19509121
Drug: 5 years
RxNorm normalized name: Dymadon 5 Years Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 years of bisphosphonate treatment
Trial: 19509121
Drug: 10 years
RxNorm normalized name: Neocate Junior Powder Children 1-10 years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 years of bisphosphonate treatment
Trial: 9207310
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m2 intravenously once a week for 3 weeks (days 1, 8, and 15) followed by a 1-week rest period.
Trial: 9207310
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 intravenously on day 1 of each 28-day cycle in combination with etoposide 100 mg/m2 on days 1, 2, and 3.
Trial: 6832198
Drug: Propranolol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0.1 mg/kg i.v.)
Trial: 25344881
Drug: SCPB (Superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCPB (Superficial Cervical Plexus Block) with 10 ml 0.25% bupivacaine each side
Trial: 26404199
Drug: Ticagrelor 270
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 270 mg loading dose
Trial: 29023473
Drug: Ticagrelor 180
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg loading dose
Trial: 26404199
Drug: Ticagrelor 360
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 360 mg loading dose
Trial: 26404199
Drug: Ticagrelor 180
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg, 270 mg, 360 mg loading doses
Trial: 29696963
Drug: Aspirin (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (control group)
Trial: 10223211
Drug: Permethrin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permethrin (200 mg/m2)
Trial: 10223211
Drug: Lambdacyhalothrin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lambdacyhalothrin (3 mg/m2)
Trial: 10223211
Drug: Lambdacyhalothrin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lambdacyhalothrin (15 mg/m2)
Trial: 8272303
Drug: Higher-dose monophasic
RxNorm normalized name: Monobasic Potassium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose monophasic pill
Trial: 8272303
Drug: Lower-dose monophasic
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose monophasic pill
Trial: 7705531
Drug: Multiphasic pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiphasic pill
Trial: 2679084
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 to 20 mg once every afternoon (stratum II)
Trial: 2679084
Drug: Gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 600 mg twice daily (both strata)
Trial: 2679084
Drug: Simvastatin 5
RxNorm normalized name: simvastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 5 to 10 mg once every afternoon (stratum I)
Trial: 2679084
Drug: Simvastatin 5
RxNorm normalized name: simvastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 5 to 10 mg once every afternoon and gemfibrozil 600 mg twice daily
Trial: 2679084
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 to 20 mg once every afternoon
Trial: 17029618
Drug: 40 tablets
RxNorm normalized name: Dextran 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 tablets (60 g) of NaP
Trial: 17029618
Drug: RF-NaP 40
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RF-NaP 40 tablets (60 g)
Trial: 12767425
Drug: L-thyroxine (L-T(4))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine (L-T(4)) replacement therapy for 6 months
Trial: 12767425
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group of 14 euthyroid patients (52.5 +/- 10 years); thyroid-stimulating hormone 2.5 +/- 1.2 microUI/ml
Trial: 4604478
Drug: Whole-cell Inaba
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-cell Inaba vaccine (2 annual injections)
Trial: 29240757
Drug: 10 session
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 session integrated cognitive behavioral therapy and HIV prevention intervention (n = 162)
Trial: 19221370
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole (80 mg bolus followed by 8 mg/h infusion for 72 hours)
Trial: 16530503
Drug: Peginterferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa‐2b monotherapy (1.5 microg/kg per week) started at week 8
Trial: 16530503
Drug: Peginterferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa‐2b monotherapy (1.5 microg/kg per week) started at week 12
Trial: 9301631
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg atorvastatin at night
Trial: 30257125
Drug: Zinc‐/copper‐containing welding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc‐/copper‐containing welding fumes (2.5 mg/m3)
Trial: 26562003
Drug: Head Massage
RxNorm normalized name: Drive Shwrhead Massager HndHld
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head Massage Therapy (HMT)
Trial: 22332874
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro insulin stimulation in infants with maternal T1D
Trial: 18538113
Drug: ZyrtecA (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZyrtecA (reference formulation)
Trial: 18538113
Drug: RyvelA (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RyvelA (test formulation)
Trial: 8751234
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily for 7 days
Trial: 11083409
Drug: Alpha-blocker treatment
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-blocker treatment
Trial: 6414271
Drug: Amipaque, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amipaque, 300 mg l/ml
Trial: 31022446
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg hydrocortisone (intervention group)
Trial: 21919922
Drug: Prazosin (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (16 mg daily)
Trial: 15039349
Drug: Vaccinated birds
RxNorm normalized name: Bird pepper
DrugBank: Bird pepper (DB14262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated birds (DNA vaccine plasmid encoding the circumsporozoite protein of P. relictum)
Trial: 9757855
Drug: Low-fat dairy
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat dairy products containing up to 1200 mg/d of calcium
Trial: 26506383
Drug: Sarcosine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarcosine (2 g daily for six months)
Trial: 21383836
Drug: Descending piano
RxNorm normalized name: Defend II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Descending piano melody exposure during the 35th, 36th, and 37th weeks of gestation, twice daily for 3 weeks.
Trial: 9541360
Drug: Potassium iodate
RxNorm normalized name: Potassium Iodate
DrugBank: Potassium iodate (DB15923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium iodate added to irrigation water (10-80 microg/l) for 2-4 weeks
Trial: 2880214
Drug: Intravenous glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glycerol (500 ml of a 10% solution in physiological saline)
Trial: 2880214
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline (500 ml administered intravenously)
Trial: 10356602
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 1500 mg daily
Trial: 6670591
Drug: Iohexol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iohexol (10 to 15 ml, 180 mg I/ml)
Trial: 12865603
Drug: High-dose heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose heparin
Trial: 10551687
Drug: Standard-dose heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose heparin
Trial: 20410427
Drug: Threshold value
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threshold value of 52 mL/m(2) for cortical renal volume-resistive index product
Trial: 17234558
Drug: MMX mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMX mesalamine 2.4 g/day given twice daily
Trial: 17234558
Drug: MMX mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMX mesalamine 4.8 g/day given once daily
Trial: 10783996
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg pantoprazole
Trial: 31096515
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg esomeprazole
Trial: 26729950
Drug: Adjunct statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct statin therapy with DMARDs
Trial: 24410484
Drug: Canrenone 25
RxNorm normalized name: canrenone
DrugBank: Canrenone (DB12221)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canrenone 25 mg
Trial: 25125488
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg
Trial: 17710010
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine (n=18)
Trial: 17710010
Drug: Patients (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients (combined treatment)
Trial: 16162697
Drug: Lansoprazole, 30
RxNorm normalized name: Lansoprazole, 30 mg oral tablet, disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole, 30 mg bid for 24 weeks
Trial: 10455094
Drug: Mivazerol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivazerol (oral administration over a two week period)
Trial: 2690660
Drug: Alcohol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (1.0 ml of 100% alcohol/kg body weight)
Trial: 30427588
Drug: Ertugliflozin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin monotherapy (15 mg)
Trial: 30427588
Drug: Ertugliflozin/Sitagliptin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin/Sitagliptin FDC (15-100 mg)
Trial: 30427588
Drug: Ertugliflozin/Metformin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin/Metformin FDC (7.5-1000 mg)
Trial: 30427588
Drug: Ertugliflozin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin monotherapy and FDCs
Trial: 30427588
Drug: Ertugliflozin/Metformin FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin/Metformin FDC
Trial: 26431906
Drug: ARA290 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARA290 (2 mg)
Trial: 24267254
Drug: Triple-therapy with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-therapy with simvastatin (40 mg daily), extended-release niacin (1500 mg daily), and ezetimibe (10 mg daily)
Trial: 24267254
Drug: Mono-therapy with
RxNorm normalized name: tiotropium bromide mono
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mono-therapy with simvastatin (40 mg daily)
Trial: 19723123
Drug: Tonabersat, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonabersat, a gap-junction modulator, well tolerated, no cardiovascular effects, pharmacokinetic profile suggests usefulness in migraine prophylaxis.
Trial: 19723123
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs and beta-blockers, commonly used preventive therapies, mechanisms of action unknown.
Trial: 15217131
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of 15 ml 2% Lidocaïne gel
Trial: 15217131
Drug: Lidocaïne periprostatic
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaïne periprostatic infiltration (10 ml of 1% Lidocaïne in two injections)
Trial: 7863993
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 and 100 mg/day)
Trial: 1645332
Drug: BV-araU 30
RxNorm normalized name: Bifidobacterium longum bv. infantis whole
DrugBank: Bifidobacterium longum infantis (DB14222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BV-araU 30 mg/day
Trial: 19787809
Drug: Boceprevir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boceprevir (400 mg twice or three times daily for 14 days)
Trial: 11575414
Drug: Intrathecal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal midazolam with bupivacaine (BM1: 1 ml of 0.5% bupivacaine plus 0.2 ml of 0.5% midazolam)
Trial: 11575414
Drug: Intrathecal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal midazolam with bupivacaine (BM2: 1 ml of 0.5% bupivacaine plus 0.4 ml of 0.5% midazolam)
Trial: 11575414
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (1 ml of 0.5% heavy bupivacaine plus 0.2 ml of 0.9% saline)
Trial: 9849260
Drug: Three noncontact
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three noncontact Therapeutic Touch treatments (15 to 20 minutes duration)
Trial: 25781525
Drug: Oral Contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Contraceptive Pills (OCP)
Trial: 30214821
Drug: Prednisolone plus
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone plus antibiotics
Trial: 788768
Drug: Antibiotic alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic alone
Trial: 26289950
Drug: Pharmacist-acquired medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-acquired medication history (MH) during admission to ED
Trial: 19135415
Drug: Palonosetron (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron (0.75 mg) with dexamethasone
Trial: 14734594
Drug: Memantine (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (starting dose 5 mg/d, increased to 20 mg/d, n = 203)
Trial: 12575607
Drug: Nitrolingual injection
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrolingual injection 15 mg in 5% glucose solution 500 ml for intravenous dripping, once a day for 2 weeks
Trial: 8163713
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug with forced titration scheme
Trial: 8163713
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug (three arms with different maximum allowable doses)
Trial: 30479020
Drug: Dose-matched attention
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose-matched attention control
Trial: 31635538
Drug: Present-centered therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present-centered therapies for PTSD
Trial: 27187320
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg E + 15 mg P (Group A)
Trial: 27187320
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg E + 20 mg P (Group B)
Trial: 27187320
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg E + 30 mg P (Group C)
Trial: 20353582
Drug: All modes
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All modes of administration
Trial: 16891634
Drug: 108 mg
RxNorm normalized name: camphor 108 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 108 mg hyperbaric articaine hydrochloride (A108)
Trial: 1740582
Drug: Ragweed immunotherapy
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ragweed immunotherapy (IT)
Trial: 25449826
Drug: Whole-body vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body vibration (WBV) therapy
Trial: 20890791
Drug: Neodolpasse(®) Infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neodolpasse(®) Infusion Solution
Trial: 15084760
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot 3.75 mg once a month for 3 months and cyproterone acetate 300 mg once a week for 3 weeks (group A)
Trial: 9757854
Drug: Nafarelin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin alone (200 microg intranasally twice daily)
Trial: 9757854
Drug: Nafarelin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin plus human parathyroid hormone‐(1‐34) (hPTH‐[1‐34]) (40 microg subcutaneously daily)
Trial: 8151606
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium (80 mmol/day) with fish oil (5 g of omega-3 fatty acids per day)
Trial: 26894151
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 μg/kg + bupivacaine local infiltration + Dexemedetomidine infusion (Loading 0.5 μg/kg, Maintenance 0.2μg/kg/hr)
Trial: 26894151
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 μg/kg + bupivacaine local infiltration
Trial: 24205786
Drug: Complementary therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary therapy (CT)
Trial: 2309645
Drug: Mackerel paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mackerel paste (135 g daily)
Trial: 27545497
Drug: TDF 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF 300mg once daily
Trial: 27545497
Drug: FTC 200mg
RxNorm normalized name: (-)-FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTC 200mg and TDF 300mg once daily
Trial: 7547078
Drug: Recombinant IFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant IFN alpha‐2b (3 x 10(6) IU 3 times weekly)
Trial: 2675757
Drug: Norfloxacin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (800 mg single dose)
Trial: 26650491
Drug: 1.8 mL
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mL of 2% lidocaine for inferior alveolar nerve block (IANB)
Trial: 16413328
Drug: Alfuzosin 10
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 10 mg once daily for 4 weeks